Alnylam Pharmaceuticals ALNY Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.71B+65.2% | $2.25B+23.0% | $1.83B+76.2% | $1.04B+22.9% | ||
| $677.17M+121% | $306.51M+14.3% | $268.22M+91.3% | $140.17M+21.9% | ||
| $3.04B+56.4% | $1.94B+24.5% | $1.56B+73.9% | $897.24M+23.0% | ||
| 81.8%-4.6pp | 86.4%+1.0pp | 85.3%-1.2pp | 86.5%+0.1pp | ||
| $1.32B+17.2% | $1.13B+12.1% | $1B+13.7% | $883.02M+11.5% | ||
| $1.21B+24.1% | $975.53M+22.6% | $795.65M+3.2% | $770.66M+24.2% | ||
| $3.21B+32.5% | $2.43B+14.9% | $2.11B+15.8% | $1.82B+17.4% | ||
| $501.58M+384% | -$176.89M+37.3% | -$282.18M+64.1% | -$785.07M-10.8% | ||
| 13.5%+21.4pp | -7.9%+7.6pp | -15.4%+60.2pp | -75.7%+8.3pp | ||
| $208.35M+46.9% | $141.86M+17.0% | $121.22M-22.3% | $155.97M+9.1% | ||
| $111.47M-8.6% | $121.99M+27.7% | $95.56M+285% | $24.81M+1,471% | ||
| -$214.07M-6.8% | -$200.49M-32.5% | -$151.34M+55.7% | -$341.92M-138% | ||
| $287.5M+176% | -$377.38M+13.0% | -$433.52M+61.5% | -$1.13B-32.3% | ||
| —— | -$99.22M-1,575% | $6.73M+61.5% | $4.16M— | ||
| $278.1M+200% | -$278.16M+36.8% | -$440.24M+61.1% | -$1.13B-32.6% | ||
| 7.5%+19.9pp | -12.4%+11.7pp | -24.1%+85.0pp | -109%-8.0pp | ||
| $2.01+193% | -$2.17+38.9% | -$3.55+61.8% | -$9.29-29.0% | ||
| $2.10+197% | -$2.17+38.4% | -$3.52+62.1% | -$9.29-29.0% | ||
| 532.3M+4.6% | 509.1M+0.8% | 505M+4.1% | 485.1M+2.7% | ||
| 522.8M+2.7% | 509.1M+2.0% | 498.9M+2.8% | 485.1M+2.7% | ||
| $4.71M-72.1% | $16.86M-60.0% | $42.19M+47.3% | $28.64M+13.9% | ||
| $10.9M— | —— | —— | —— | ||
| $292.52M+201% | -$289.3M+30.9% | -$418.96M+63.3% | -$1.14B-35.6% | ||
| -$2.2M+97.9% | -$106.76M-14,874% | -$713K+50.2% | -$1.43M— | ||
| $55.66M-1.8% | $56.67M+4.8% | $54.05M+21.6% | $44.47M-6.5% | ||
| —— | $14.36M+138% | $6.02M+127% | $2.65M— | ||
| —— | $86.55M— | —— | $45.6M-56.8% | ||
| -$52.94M+77.5% | -$235.45M-528% | $55.02M+183% | -$66.07M— | ||
| —— | -$13.59M+26.0% | -$18.37M-154% | $34.14M+29.2% | ||
| $124.5M+3,956% | -$3.23M— | —— | —— | ||
| $218.71M+224% | $67.58M+110% | $32.12M-29.0% | $45.24M— | ||
| —— | $294.16M+70.9% | $172.13M-59.6% | $425.75M-65.9% | ||
| $473.5M— | —— | -$336.35M— | —— | ||
| $524.08M+6,405% | -$8.31M— | —— | -$541.27M+15.6% | ||
| $1.82M+45,550% | -$4K-100% | $11.02M— | —— | ||
| $5.2M+103% | -$180.62M-43.7% | -$125.68M+6.3% | -$134.18M-5,267% | ||
| —— | -$38.99M-1,539% | -$2.38M-1,244% | -$177K— | ||
| $1.31B-20.2% | $1.63B-10.3% | $1.82B-7.8% | $1.98B+19.4% | ||
| $58.7M+71.2% | $34.28M-44.9% | $62.21M-13.7% | $72.06M-5.6% | ||
| $250.03M-17.5% | $302.95M+105% | $147.46M-43.1% | $259.36M+5.3% | ||
| $3.71B+65.2% | $2.25B+23.0% | $1.83B+76.2% | $1.04B— | ||
| $348.24M+28.0% | $272.08M+22.7% | $221.68M-3.9% | $230.65M+39.2% | ||
| $501.58M+384% | -$176.89M+37.3% | -$282.18M+64.1% | -$785.07M-10.8% | ||
| $557.24M+564% | -$120.22M+47.3% | -$228.12M+69.2% | -$740.6M-12.0% | ||
| $557.24M+564% | -$120.22M+47.3% | -$228.12M+69.2% | -$740.6M-12.0% | ||
| 15%+20.4pp | -5.3%+7.1pp | -12.5%+58.9pp | -71.4%+6.9pp | ||
| $501.58M+384% | -$176.89M+37.3% | -$282.18M+64.1% | -$785.07M-10.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Alnylam Pharmaceuticals's revenue?
- Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.
- Is Alnylam Pharmaceuticals profitable?
- Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.
- What are Alnylam Pharmaceuticals's profit margins?
- Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.
- What is Alnylam Pharmaceuticals's earnings per share?
- Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.
- Where does Alnylam Pharmaceuticals's income statement data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
